

June 29, 2010



Stellar Biotechnologies Appoints John S. Sundsmo, Ph.D. to VP, Research & IP Management and Daniel C. Adelman, M.D. as Member of SAB

PORT HUENEME, CA -- (MARKET WIRE) -- 06/29/10 -- *Stellar Biotechnologies, Inc.* (PINKSHEETS: SBOTF) (TSX-V: KLH) has appointed John S. Sundsmo, Ph.D., VP - Research & Intellectual Property Management and Daniel C. Adelman, M.D. as a member of the Scientific Advisory Board.

Executive VP, Daniel E. Morse, Ph.D., said, "Adding a scientific talent with strong patent-focus like John Sundsmo is significant. The importance of our platform technologies and proprietary IP cannot be overemphasized, and Dr. Sundsmo's contribution to success for our shareholders and for patients with serious disease should be great."

SAB Chairman, Andrew Saxon, M.D., said, "I have known Dan Adelman and respected his work for years. His keen, scientific and medical mind, strong corporate executive skills, leading teams in both biotech and pharmaceutical companies, at startups like Alvine Pharmaceuticals as well as large companies like Genentech, and his deep understanding of all stages of the drug development process will be of tremendous benefit to Stellar."

Dr. Sundsmo's background blends business, IP and research experience gained at Collagen Corporation, Triton Biosciences/Royal Dutch Shell, TransCell Therapeutics, Viagene and others, and in law firms, Christensen, O'Connor (Seattle) and Weiss, Jensen (Seattle/Portland). A registered U.S. Patent Agent, he earned his Ph.D. in Microbiology/Immunology at the University of Washington with post-doctoral studies in Molecular Oncology at Fred Hutchinson Cancer Research Center and Molecular Immunology at Scripps Research Institute.

Dr. Adelman serves as Adjunct Professor of Medicine at UC-San Francisco. He has also been working in the biotechnology industry. He is currently Senior VP, Development and Chief Medical Officer at Alvine Pharmaceuticals. Prior to that, Dr. Adelman was Senior VP, Development and Chief Medical Officer at Sunesis Pharmaceuticals. He served in various roles at Pharmacyclics, including VP, Clinical Operations and Biometrics and was a Clinical Scientist at Genentech. Dr. Adelman has been involved in all stages of pharmaceutical drug development and shared responsibility for the early development of Xolair and Avastin. Dr. Adelman holds a BA in Biology from the University of California and an M.D. degree from the UC-Davis. After completing his residency in Internal Medicine at Cedars-Sinai Medical Center in Los Angeles, he did post-doctoral fellowship

training in Clinical Immunology and Allergy at UCLA.

Dr. Sundsmo said, "Stellar's mandate to expand KLH use as a cancer vaccine carrier, immune stimulant and neo-antigen for immune status monitoring really excites me. The timing has never been better. Building the technology in-house, with CROs and partners should enable us to optimize our intellectual property base while building highly effective product platforms. Existing agreements offer promising opportunities to expand Stellar's international position and revenues. New advances in individualized cancer therapy offer us rather unique abilities to work with, and serve, patients and physicians in a common quest to generate new life-saving vaccines, diagnostics and therapies. Bringing these to market will be very satisfying."

Dr. Adelman said, "As a clinical immunologist working in the biotechnology industry, I am very much looking forward to sharing my experiences in developing immunotherapeutics with the Stellar team. I share Stellar's vision of advancing their innovative technology platform to develop novel immune-based therapeutics for serious illnesses."

About Stellar Biotechnologies, Inc. (PINKSHEETS: SBOTF) (TSX-V: KLH): Stellar's product, KLH, is a potent immuno-stimulatory protein with an exceptional record of safety and non-toxicity in humans that is being used in medicines known as conjugate therapeutic vaccines and in other biomedical products. Already a world leader in the production of KLH, Stellar plans to further monetize its KLH production platform and maximize the commercial impact of its intellectual property portfolio through the physical sourcing, purification and supply of medical-grade KLH. KLH is exclusively sourced from the blood of the rare keyhole limpet and Stellar has technology for the maintenance of that animal, as well as a non-lethal extraction method of the critical molecule and refinement process for KLH that it currently sells into growing academic, research, pharmaceutical markets.

Statements in this press release other than purely historical factual information, including statements relating to revenues or profits, or the Company's future plans and objectives, or expected sales, cash flows, and capital expenditures constitute forward-looking statements. Forward-looking statements are based on numerous assumptions and are subject to all of the risks and uncertainties inherent in the Company's business, including risks inherent in the technology history. There can be no assurance that such forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact:

Darrell Brookstein

VP

dbrookstein@stellarbiotech.com

858 449 2523